Dillon & Associates Inc. Purchase 1,188 Shares of Celgene Co. (CELG)

Dillon & Associates Inc. Purchase 1,188 Shares of Celgene Co. (CELG)

Dillon & Associates Inc. increased its position in shares of Celgene Co. (NASDAQ:CELG) by 2.7% during the first quarter, Holdings Channel reports. The firm owned 44,778 shares of the biopharmaceutical company’s stock after buying an additional 1,188 shares during the period. Celgene accounts for approximately 2.4% of Dillon & Associates Inc.’s portfolio, making the stock its 16th largest position. Dillon & Associates Inc.’s holdings in Celgene were worth $5,552,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the stock. Diversified Trust Co raised its position in shares of Celgene by 0.4% in the first quarter. Diversified Trust Co now owns 2,342 shares of the biopharmaceutical company’s stock worth $291,000 after buying an additional 9 shares during the period. Arete Wealth Advisors LLC raised its position in shares of Celgene by 0.3% in the third quarter. Arete Wealth Advisors LLC now owns 3,106 shares of the biopharmaceutical company’s stock worth $325,000 after buying an additional 10 shares during the period. Hodges Capital Management Inc. raised its position in shares of Celgene by 0.8% in the fourth quarter. Hodges Capital Management Inc. now owns 2,152 shares of the biopharmaceutical company’s stock worth $249,000 after buying an additional 17 shares during the period. First Heartland Consultants Inc. raised its position in shares of Celgene by 0.5% in the third quarter. First Heartland Consultants Inc. now owns 5,914 shares of the biopharmaceutical company’s stock worth $618,000 after buying an additional 30 shares during the period. Finally, Quadrant Capital Group LLC raised its position in shares of Celgene by 0.8% in the first quarter. Quadrant Capital Group LLC now owns 4,073 shares of the biopharmaceutical company’s stock worth $492,000 after buying an additional 34 shares during the period. Institutional investors and hedge funds own 77.68% of the company’s stock.

Celgene Co. (CELG) opened at 118.73 on Friday. Celgene Co. has a 52 week low of $94.42 and a 52 week high of $127.64. The company has a 50-day moving average of $120.53 and a 200 day moving average of $119.80. The company has a market cap of $92.71 billion, a P/E ratio of 44.59 and a beta of 1.74.

Celgene (NASDAQ:CELG) last released its quarterly earnings results on Thursday, April 27th. The biopharmaceutical company reported $1.68 EPS for the quarter, topping the Zacks’ consensus estimate of $1.47 by $0.21. Celgene had a net margin of 17.80% and a return on equity of 77.95%. The business had revenue of $2.96 billion during the quarter, compared to analysts’ expectations of $3.04 billion. During the same quarter in the previous year, the company earned $1.32 EPS. The business’s quarterly revenue was up 17.8% compared to the same quarter last year. On average, equities analysts forecast that Celgene Co. will post $7.29 EPS for the current fiscal year.

A number of brokerages recently commented on CELG. Cantor Fitzgerald set a $159.00 price target on shares of Celgene and gave the company a “buy” rating in a research note on Saturday, February 18th. Credit Suisse Group AG set a $148.00 price target on shares of Celgene and gave the company a “buy” rating in a research note on Saturday, February 18th. JPMorgan Chase & Co. reiterated a “buy” rating on shares of Celgene in a research note on Saturday, February 18th. Oppenheimer Holdings Inc. set a $148.00 price target on shares of Celgene and gave the company a “buy” rating in a research note on Saturday, February 25th. Finally, Canaccord Genuity set a $156.00 price target on shares of Celgene and gave the company a “buy” rating in a research note on Saturday, February 25th. One analyst has rated the stock with a sell rating, six have assigned a hold rating, nineteen have assigned a buy rating and one has assigned a strong buy rating to the company. The stock currently has a consensus rating of “Buy” and an average price target of $139.05.

In other Celgene news, Director James J. Loughlin sold 9,250 shares of the business’s stock in a transaction that occurred on Monday, May 1st. The shares were sold at an average price of $124.00, for a total value of $1,147,000.00. Following the completion of the transaction, the director now owns 32,169 shares of the company’s stock, valued at approximately $3,988,956. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, Director Gilla Kaplan sold 14,033 shares of the business’s stock in a transaction that occurred on Thursday, March 30th. The stock was sold at an average price of $123.83, for a total transaction of $1,737,706.39. Following the completion of the transaction, the director now directly owns 73,109 shares of the company’s stock, valued at approximately $9,053,087.47. The disclosure for this sale can be found here. 0.97% of the stock is owned by insiders.

About Celgene

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.new TradingView.widget({ “height”: 400, “width”: 625, “symbol”: “NASDAQ:CELG”, “interval”: “D”, “timezone”: “Etc/UTC”, “theme”: “White”, “style”: “1”, “locale”: “en”, “toolbar_bg”: “#f1f3f6”, “enable_publishing”: false, “hideideas”: true, “referral_id”: “2588”});

Want to see what other hedge funds are holding CELG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celgene Co. (NASDAQ:CELG).

Related posts

Leave a Comment